Silk Road Medical Inc
Change company Symbol lookup
Select an option...
SILK Silk Road Medical Inc
LYLT Loyalty Ventures Inc
BOXD Boxed Inc
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Closing Price
$41.60
Day's Change
0.75 (1.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
42.05
Day's Low
39.93
Volume
(Average)
Volume:
738,199

10-day average volume:
708,670
738,199

Company Profile

Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
11.33x
Price/Book (MRQ)
9.56x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

February 2023
Current Month
2.2M
Previous Month
1.9M
Percent of Float
5.97%
Days to Cover
4.5136 Days

Share Information

SILK is in a share class of common stock
Float
37.1M
Shares Outstanding
38.5M
Institutions Holding Shares
266
105.42%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jack W. Lasersohn
  • Erica J. RogersPres.
  • Lucas W. BuchananCFO
  • Richard M. RuedyExec.VP
  • Mhairi JonesCAO

Address

Insider Trading

During the most recent quarter, 344K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.